MIR22HG
Putative uncharacterized protein encoded by MIR22HG
Also known as: CQ091_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for MIR22HG in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
57 residues, UniProt reviewed canonical sequence.
>Q0VDD5|MIR22HG
1 MGWEGPNSRV DDTFWASWRA FAQIGPARSG FRLETLAGLR SRRLKQPKAF CLRDVAPLocalizationUniProt · AlphaFold · HPA
Whether an antibody against MIR22HG can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.59
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MIR22HG as an antibody target. Whether an autoantibody or antibody against MIR22HG could matter depends on whether native MIR22HG is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MIR22HG is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label MIR22HG as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...